EMA adopted an extension to the indication of Ruconest to include children from the age of 2 years and above for the treatment of acute angioedema attacks
On 26 March 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ruconest (conestat alfa). The marketing authorisation holder for this medicinal product is Pharming Group N.V. The Committee for Medicinal Products for Human Use (CHMP)